Popular - Bioinformatics(Emerging Tech)
Updated: 55 Days AgoBioinformatics
- Foundation models for histology and multimodal biomedical data.
- H-Optimus line focuses on digital pathology and tissue embeddings.
- M-Optimus line targets cross-modal biology and patient context.
- API and enterprise paths for labs standardizing on shared encoders.
- Therapeutics R&D built on RNA biology and splicing models.
- Designs oligonucleotide-style candidates from genomic-scale data.
- End-to-end story from target rationale to clinical development.
- Strong example of sequence-first AI in drug programs.
- Structure-based virtual screening with learned scoring models.
- Screens large libraries for novel hits against crystal structures.
- Runs partnered discovery campaigns with pharma and biotech.
- Useful default when teams want AI-first docking at scale.
- Generative AI for antibody sequences and developability.
- Tight loop between models, assays, and partner pipelines.
- Pharma collaborations on AI-enabled biologics discovery.
- Often cited where ML meets wet-lab antibody engineering.
- Foundry-scale organism engineering with heavy lab automation.
- Software and data stack for strain design and screening.
- Partners across pharma, agriculture, and industrial biotech.
- Public company tied to large-scale synthetic biology programs.
- ML-first drug discovery on large in-house phenomic datasets.
- Combines cellular models, genetics, and machine learning.
- Partners with major pharma on targets and pathways.
- Industrialized wet-lab plus compute feedback loops.
- Deep learning system for predicting 3D protein structures.
- Open databases and APIs used across structural biology.
- Default starting point from sequence to plausible folds.
- Drives wet-lab planning, screens, and structural follow-up.
- Industrialized cellular imaging plus ML for phenotypes.
- Maps biology at scale to surface novel small-molecule ideas.
- Partners with large biopharma on discovery programs.
- Known for automation-heavy labs and vast image datasets.
- Computational small-molecule discovery with deep ML roots.
- Evolves the Atomwise-era platform toward broader pipelines.
- Strong focus on immune and inflammatory disease biology.
- Combines modeling with wet-lab cycles to advance candidates.